209 related articles for article (PubMed ID: 8931812)
21. Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients.
Higuchi K; Yamashita D; Kashihara Y; Kakara M; Hirota T; Hirakawa M; Ieiri I
Ther Drug Monit; 2019 Oct; 41(5):674-680. PubMed ID: 31095070
[TBL] [Abstract][Full Text] [Related]
22. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin.
Ramsay RE; Wilder BJ; Uthman BM; Garnett WR; Pellock JM; Barkley GL; Leppik IE; Knapp LE
Epilepsy Res; 1997 Oct; 28(3):181-7. PubMed ID: 9332883
[TBL] [Abstract][Full Text] [Related]
23. Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study.
Ohno Y; Niwa T; Hirai K; Suzuki K; Yamada Y; Hayashi Y; Hayashi H; Suzuki A; Itoh Y
Ther Drug Monit; 2018 Aug; 40(4):507-511. PubMed ID: 29683874
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus.
Srivastava K; Bhartiya S; Gavli V; Patil R; Rajadhyaksha S
Indian Pediatr; 2020 Mar; 57(3):218-221. PubMed ID: 32198860
[TBL] [Abstract][Full Text] [Related]
25. A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children.
Clay JL; Fountain NB
Expert Rev Neurother; 2022 Jan; 22(1):1-13. PubMed ID: 34726961
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.
Tanaka J; Kasai H; Shimizu K; Shimasaki S; Kumagai Y
Eur J Clin Pharmacol; 2013 Mar; 69(3):489-97. PubMed ID: 22918614
[TBL] [Abstract][Full Text] [Related]
27. Fosphenytoin. Pharmacoeconomic implications of therapy.
Holliday SM; Benfield P; Plosker GL
Pharmacoeconomics; 1998 Dec; 14(6):685-90. PubMed ID: 10346419
[TBL] [Abstract][Full Text] [Related]
28. Fosphenytoin sodium: new drug to replace intravenous phenytoin sodium.
Voytko SM; Farrington E
Pediatr Nurs; 1997; 23(5):503-6. PubMed ID: 9355589
[No Abstract] [Full Text] [Related]
29. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats.
Burstein AH; Cox DS; Mistry B; Eddington ND
Epilepsy Res; 1999 Apr; 34(2-3):129-33. PubMed ID: 10210027
[TBL] [Abstract][Full Text] [Related]
30. Phenytoin penetration into brain after administration of phenytoin or fosphenytoin.
Walton NY; Uthman BM; El Yafi K; Kim JM; Treiman DM
Epilepsia; 1999 Feb; 40(2):153-6. PubMed ID: 9952260
[TBL] [Abstract][Full Text] [Related]
31. Fosphenytoin in infants.
Takeoka M; Krishnamoorthy KS; Soman TB; Caviness VS
J Child Neurol; 1998 Nov; 13(11):537-40. PubMed ID: 9853645
[TBL] [Abstract][Full Text] [Related]
32. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration.
Ogutu BR; Newton CR; Muchohi SN; Otieno GO; Kokwaro GO
Br J Clin Pharmacol; 2002 Dec; 54(6):635-42. PubMed ID: 12492612
[TBL] [Abstract][Full Text] [Related]
33. Pediatric use of intravenous and intramuscular phenytoin: lessons learned.
Wheless JW
J Child Neurol; 1998 Oct; 13 Suppl 1():S11-4; discussion S30-2. PubMed ID: 9796746
[TBL] [Abstract][Full Text] [Related]
34. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.
DeToledo JC; Ramsay RE
Drug Saf; 2000 Jun; 22(6):459-66. PubMed ID: 10877039
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Intravenous Phenytoin and Fosphenytoin Loading Doses: Influence of Obesity and Sex.
DasGupta R; Alaniz C; Burghardt D
Ann Pharmacother; 2019 May; 53(5):458-463. PubMed ID: 30522345
[TBL] [Abstract][Full Text] [Related]
36. Impact of Body Habitus on Phenytoin Levels Following Fosphenytoin Loading Dose in Pediatric Patients.
Messinger MM; Moffett BS; Wilfong A
Ther Drug Monit; 2015 Dec; 37(6):772-5. PubMed ID: 26402424
[TBL] [Abstract][Full Text] [Related]
37. Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.
Kugler AR; Annesley TM; Nordblom GD; Koup JR; Olson SC
Clin Chem; 1998 Jul; 44(7):1474-80. PubMed ID: 9665426
[TBL] [Abstract][Full Text] [Related]
38. Nose-to-brain delivery of phenytoin and its hydrophilic prodrug fosphenytoin combined in a microemulsion - formulation development and in vivo pharmacokinetics.
Pires PC; Fazendeiro AC; Rodrigues M; Alves G; Santos AO
Eur J Pharm Sci; 2021 Sep; 164():105918. PubMed ID: 34174414
[TBL] [Abstract][Full Text] [Related]
39. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.
Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ
Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711
[TBL] [Abstract][Full Text] [Related]
40. Effect of therapeutic plasma exchange on phenytoin plasma concentration in patients receiving intravenous fosphenytoin therapy.
Nishida S; Hayashi Y; Hirai K; Takekoshi A; Yamada Y; Kobayashi R; Shimizu S; Niwa T; Hayashi H; Shimohata T; Sugiyama T; Suzuki A
Pharmazie; 2020 Oct; 75(10):488-490. PubMed ID: 33305722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
